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Organic nitrates are a group of very eﬀective anti-ischemic drugs. They are used for the treatment of patients with stable angina,
acute myocardial infarction, and chronic congestive heart failure. A major therapeutic limitation inherent to organic nitrates is
the development of tolerance, which occurs during chronic treatment with these agents, and this phenomenon is largely based on
induction of oxidative stress with subsequent endothelial dysfunction. We therefore speculated that induction of heme oxygenase-
1 (HO-1) could be an eﬃcient strategy to overcome nitrate tolerance and the associated side eﬀects. Indeed, we found that hemin
cotreatment prevented the development of nitrate tolerance and vascular oxidative stress in response to chronic nitroglycerin
therapy. Vice versa, pentaerithrityl tetranitrate (PETN), a nitrate that was previously reported to be devoid of adverse side eﬀects,
displayed tolerance and oxidative stress when the HO-1 pathway was blocked pharmacologically or genetically by using HO-1+/−
mice. Recently, we identiﬁed activation of Nrf2 and HuR as a principle mechanism of HO-1 induction by PETN. With the present
paper, we present and discuss our recent and previous ﬁndings on the role of HO-1 for the prevention of nitroglycerin-induced
nitrate tolerance and for the beneﬁcial eﬀects of PETN therapy.
1. OrganicNitrateTherapy andSide Effects
Nitroglycerin (GTN) has been one of the most widely used
anti-ischemic drugs for more than a century. Given acutely,
organic nitrates are excellent agents for the treatment of
stable eﬀort angina, acute myocardial infarction, chronic
congestive heart failure, pulmonary edema, and severe arte-
rial hypertension (for review see [1, 2]). The chronic eﬃcacy
of nitrates, however, is blunted due to the development of
nitrate tolerance and endothelial dysfunction, phenomena
that are largely associated with increased vascular oxidative
stress (for review see [1–5]). Oxidative stress was demon-
strated to be a hallmark of most cardiovascular diseases [6].
The term oxidative stress deﬁnes a state with either increased
formation of reactive oxygen and nitrogen species (RONS)
and/or impaired cellular antioxidant defense system (e.g.,
downregulation of important antioxidant proteins) with
subsequent depletion of low-molecular-weight antioxidants
and a shift in the cellular redox balance. The central role of
the endothelium for the regulation of vascular tone makes
it a vulnerable target for RONS which can interfere at many
positions with the NO/cGMP signaling cascade [7].
It is well established that most organic nitrates cause
nitrate tolerance and/or cross-tolerance to endothelium-
dependent vasodilators (e.g., acetylcholine) [8–11]. The ﬁrst
report on a role for oxidative stress in the development
of nitrate tolerance was published in 1995 by M¨ unzel and
coworkers for nitroglycerin therapy [12]. These authors
found that superoxide levels were twofold higher in aortic2 International Journal of Hypertension
segments from nitrate tolerant vessels with intact endothe-
lium. Based on these ﬁndings, they suspected that the
enhancedlevelsofsuperoxideinnitroglycerintolerantvessels
mightcontributenotonlytonitroglycerintolerance,butalso
to cross-tolerance to 3-morpholinosydnonimine (Sin-1) and
endogenous NO production stimulated by acetylcholine. To
test this hypothesis, they examined the eﬀects of bovine Cu,
Zn-superoxide dismutase (SOD) entrapped in pH sensitive
liposomes. In nitroglycerin-tolerant aortic segments with
endothelium, liposomal SOD markedly enhanced the relax-
ations evoked by nitroglycerin, Sin-1, and acetylcholine. The
source of RONS formation in the setting of nitrate tolerance
was ﬁrst found to be NADH oxidase. This ﬁnding was
mainly based on the observation that the superoxide signal
was most pronounced in the presence of NADH and that
it was located in the particulate and not cytosolic fraction
[13]. More compelling data came from the observation
that the protein kinase C inhibition eﬀectively suppressed
nitroglycerin-induced vascular RONS formation and vaso-
constrictor supersensitivity in tolerant vessels, keeping in
mind that protein kinase C activates NADPH oxidase [14,
15].
Since nitroglycerin is thought to release NO and induce
superoxide formation simultaneously, the formation of
peroxynitrite from the reaction of NO and superoxide could
beexpected.Indeed,somestudieshavereportedonincreased
levels of tyrosine-nitrated proteins, which is a marker for
increased peroxynitrite formation in tissue from nitrate-
tolerant animals [16]. We could also identify higher con-
centrations of nitrated prostacyclin synthase and decreased
prostacyclin levels in these animals [17]. Indirect proof
for a role of peroxynitrite for nitrate tolerance came from
the observation that hydralazine, which eﬃciently improves
nitrate tolerance, is a powerful peroxynitrite scavenger
and inhibitor of protein tyrosine nitration [18]. Moreover,
authentic or in situ generated (Sin-1-derived) peroxynitrite
was most eﬃcient in inhibiting the bioactivating enzyme of
nitroglycerin [19]. In addition, three independent reports
provided data that peroxynitrite plays a central role in the
development and pathogenesis of nitrate tolerance [20–22].
The concept of NAD(P)H oxidase-driven RONS for-
mation as the most important source of oxidative stress
in nitrate tolerance was accepted for almost 10 years. In
2004, we reported for the ﬁrst time on mitochondrial ROS
formation in nitroglycerin induced tolerance [23], although
bioactivation of nitroglycerin by mitochondrial aldehyde
dehydrogenase (ALDH-2) was already reported 2 years ear-
lier [24]. Despite the fact that the harmful eﬀects of organic
nitrates on mitochondria have already been described in the
1960sbyNeedlemanandcoworkers(mitochondrialswelling,
thiol depletion, and impaired respiration) [25, 26], it took
more than 40 years to reveal the pivotal role of mitochondria
in nitroglycerin toxicity [23, 24, 27]. To test this hypothesis,
we used mice with heterozygous Mn-SOD deﬁciency (Mn-
SOD+/−), which is the mitochondrial isoform of superox-
ide dismutases [28, 29]. Nitroglycerin-driven vascular and
mitochondrial ROS formation was increased in Mn-SOD+/−
mice, and, vice versa, the ALDH-2 activity in these samples
was decreased by nitroglycerin in a more pronounced
manner. Moreover, nitroglycerin potency was signiﬁcantly
impaired in response to low-dose nitroglycerin in vivo
treatment indicating the development of nitrate tolerance
by this low dose in Mn-SOD+/− mice but not in wild-
type controls. The detrimental role of mitochondrial RONS
formation for the development of GTN-induced nitrate
tolerance was further supported by a subsequent report on
the prevention of GTN side eﬀects by the mitochondria-
targeted antioxidant mitoquinone (mitoQ) [30].
2. EffectsofHO-1InductionandSuppressionon
NitrateTolerance and OxidativeStress
With a previous study, we demonstrated that chronic nitro-
glycerin (GTN) therapy results in impaired vasodilatory
potency of GTN (nitrate tolerance) and of the endothelium-
dependent vasodilator acetylcholine (endothelial dysfunc-
tion) as well as increased vascular and mitochondrial RONS
formation [31]. Since another organic nitrate (PETN) was
previously described to be devoid of nitrate tolerance and
induction of oxidative stress due to induction of the heme
oxygenase-1 (HO-1) system [35, 36], we hypothesized that
pharmacological activation of the HO-1 system may be suit-
abletopreventGTN-dependentsideeﬀects.Indeed,cotreat-
ment of GTN-infused rats with the potent HO-1 inducer
hemin completely prevented nitrate tolerance (restored the
GTN-dependent relaxation), restored NO/cGMP signaling,
increased the activity of the GTN bioactivating enzyme
ALDH-2, and suppressed the mitochondrial RONS forma-
tion (Figures 1(a)–1(c))[ 31]. The HO-1 product bilirubin
suppressed GTN-induced RONS formation in isolated heart
mitochondria (Figure 1(d)). To test the essential role of
HO-1 for the tolerance devoid action of PETN, we cotreated
PETN-infused rats with the HO-1 suppressor apigenin and
observed a tolerance-like phenomenon displaying impaired
PETN-dependentrelaxation,disturbedNO/cGMPsignaling,
andincreasedmitochondrialRONSformation(Figures1(e)-
1(f))[ 31].
These observations are in good accordance with pre-
vious reports on HO-1 induction by statins [37, 38]a n d
preventionofnitratetoleranceinGTN-infusedexperimental
animals [39] as well as human individuals [40, 41]. The
role of HO-1 for prevention of organic nitrate induced
tolerance, endothelial dysfunction, and oxidative stress is
further supported by observations that the HO-1 product
bilirubin eﬃciently scavenged GTN-induced RONS (most
probably peroxynitrite) formation in isolated mitochondria
[29, 31]. Likewise, the HO-1 products bilirubin and carbon
monoxide as well as PETN increased the expression of
the GTP-cyclohydrolase-1 (GCH-1), the most important
enzyme for de novo synthesis of tetrahydrobiopterin (BH4),
an essential cofactor for endothelial NO synthase (eNOS)
function[34,42]. In contrast,GTNin vivo therapy decreased
the expression of the GCH-1 [43]. Since BH4 levels are
directlylinkedtoeNOSactivityandendothelialfunction[44,
45] and GCH-1 is oxidatively degraded by activation of the
proteasome26S [46], activation of antioxidant pathways by
induction of HO-1 may represent an attractive explanation
for the tolerance and endothelial dysfunction devoid proﬁleInternational Journal of Hypertension 3
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Figure 1: Eﬀects of the HO-1 inducer hemin on GTN-induced tolerance and eﬀects of the HO-1 suppressor apigenin on PETN side eﬀects.
Hemin (25mg/kg) was administrated by single i.p. injection on day 3 of GTN treatment (6.6μg/kg/min for 4days via s.c. infusion) and
markedly improved vascular GTN responsiveness (see area between curves) as demonstrated by isometric tension studies (a), a signiﬁcant
decrease in mitochondrial ROS formation (b), and improvement of mitochondrial ALDH-2 activity (c). Eﬀects of bolus bilirubin on ROS
formation in isolated heart mitochondria from GTN in vivo treated rats were determined by L-012 (100μM) ECL in the presence of 2.5mM
succinate and bilirubin (0–25μM) (d). Apigenin (10mg/kg/d) was coinfused over 4d together with PETN (10.5μg/kg/min for 4days via s.c.
infusion). Apigenin cotreatment decreased PETN vasodilator potency (see area between curves) and induced a tolerance-like right shift in
the PETN concentration-relaxation-curve (E). This observation was accompanied by increased mitochondrial ROS formation (F). Data are
mean±SEM of n = 8–12 (a), 40 (b), 6–18 (c), 4–6 (d), 9–11 (e), and 28–43 (f) independent experiments.
∗P < 0.05 versus GTN or PETN
treatment. Modiﬁed from [31].
of chronic PETN therapy and the undesired side eﬀects
of most other organic nitrates (but most pronounced
for GTN treatment). Similar observations were made for
extracellular superoxide dismutase (ecSOD), a downstream
target of HO-1 and its products [47], which is upregulated
by PETN [34, 48] but not by isosorbide-5-mononitrate
(ISMN). Moreover, it was recently reported that HO-1 plays
a signiﬁcant role in the maintenance of soluble guanylyl
cyclase (sGC) in a reduced heme state providing another
important function for HO-1 in the regulatory pathways of
vascular tone [49]. This novel beneﬁcial property of HO-1
could also signiﬁcantly improve vascular dysfunction in the
setting of nitrate tolerance. These observations underline
the distinct properties of organic nitrates, and these drugs
do not represent a class with homogeneous eﬀects [50]b u t
also challenge the traditional assumption that all organic
nitrates release the same vasoactive species (nitric oxide)—
an assumption that was already challenged for GTN in 2003
[51]( a n dr e v i e w e di n[ 1, 5]).
In addition, previous work has demonstrated that
organic nitrates have distinct eﬀects on the function and
survival of circulating angiogenic cells (formally known as4 International Journal of Hypertension
endothelial progenitor cells) [52, 53]. These studies showed
that isosorbide dinitrate in contrast to PETN impair the
migration and incorporation activities of these circulating
angiogenic cells in an experimental model of myocardial
infarction, whereas GTN in vitro exposure increased apop-
tosis while decreasing phenotypic diﬀerentiation, migration,
and mitochondrial dehydrogenase activity in these cells. In a
subsequent study, Lin et al. investigated the involvement of
heme oxygenase-1 for the related neovascularization process
by hematopoietic stem cells and endothelial progenitor cells
in the infarcted area [54]. Thum et al. have shown that
the impaired function of these circulating angiogenic cells
is based on oxidative stress as envisaged in the setting of
diabetes, leading to eNOS uncoupling, which was improved
by antioxidants (e.g., superoxide dismutase) [55]. These
ﬁndings underline the importance of maintaining the BH4
levels to prevent eNOS uncoupling and the role of HO-1 for
this antioxidant mechanism via increase in GCH-1 expres-
sion by carbon monoxide and bilirubin as outlined above.
Thisconceptisfurthersupportedbyprotectiveeﬀectsoffolic
acid (a precursor of BH4) on impaired endothelial function
in GTN-treated healthy volunteers [56], and decreased BH4
levels in GTN-treated rabbits were restored by cotherapy
withpioglitazone[57].Itshouldbenotedthatanothergroup
found no association between aortic BH4 content and eNOS
function in response to GTN ex vivo and in vivo treatment
[58].
Finally, it should be mentioned that oxidative stress
in response to organic nitrates may also be protective
by a process called ischemic preconditioning (IPC) [59–
61]. Recently, the involvement of HO-1 in organic nitrate-
mediatedIPCwasproposed[59,62]asanexplanationforthe
sustained IPC protective eﬀect under chronic PETN therapy
b u tl o s so ft h i sb e n e ﬁ c i a le ﬀect under chronic GTN therapy.
This is in accordance with the accepted view that HO-1 plays
ar o l ei nI P C[ 63, 64].
3. Molecular Proof of a Role of
HO-1 for the Tolerance-Devoid Proﬁle of
PETNbyUsing HO-1+/− Mice
The role of HO-1 as the antioxidative principle of PETN
was elucidated by 3-key experiments aiming to prove this
hypothesis at a molecular basis [32]. The ﬁrst experimental
setup consisted of the treatment of control (HO-1+/+)
and partially deﬁcient (HO-1+/−) mice with PETN. In
HO-1+/− but not HO-1+/+ mice, PETN infusion induced
desensitization to PETN-induced vasorelaxation (envisaged
byimpairedvasodilatorpotencyofthedruginisolatedaortic
segments) and increased mitochondrial ROS formation
(Figures 2(a) and 2(b)), demonstrating nitrate tolerance to
PETN in a setting of HO-1 deﬁciency. The second approach
was on the basis of HO-1 induction by the known inducer of
this enzyme, hemin, which improved angiotensin-II-(high-
dose) dependent endothelial dysfunction and prevented
activation of NADPH oxidase in HO-1+/+ mice (Figures
2(c) and 2(d)). The third experiment demonstrated that
PETN did not improve endothelial dysfunction and cardiac
oxidative stress in angiotensin-II-(low-dose) treated HO-
1+/− mice but further impaired vascular function and
increased ROS formation in this setting (Figure 2(e) and
2(f)). It is somewhat surprising that already heterozygous
deﬁciency in HO-1 leads to complete loss of the beneﬁcial
and protective eﬀects of PETN but may also underline how
essential the upregulation of HO-1 is to prevent nitrate tol-
erance, endothelial dysfunction, and oxidative stress under
chronic therapy with organic nitrates. It would be of great
clinicalimportancetostudythevasodilatorypotencyofGTN
and development of nitrate tolerance under chronic GTN
therapy in human individuals with Morbus Meulengracht
(Gilbert’s syndrome) to translate our preclinical data from
bench to bedside and to further explore the therapeutical
potential of HO-1 induction to overcome the side eﬀects of
GTNtherapy.Sincehumansubjectswithhyperbilirubinemia
(e.g., new born with mild jaundice or patients with Gilbert’s
syndrome) have a better prognosis and have a signiﬁcant
lower cardiovascular risk [65], it may be hypothesized that
they will also display a lower degree of nitrate tolerance in
response to chronic GTN therapy.
The beneﬁcial eﬀects of HO-1 induction on mitochon-
d r i a lR O N Sf o r m a t i o nm a yb ea t t r i b u t e dt ot h ep r e s e n c e
of HO-1 in mitochondria [66] and the improvement of
mitochondrial biogenesis as well as suppression of doxoru-
bicin cardiotoxicity [67]. Recent report also suggests that
targeting HO-1 to mitochondria can prevent inﬂammation-
triggered mitochondrial oxidative stress and apoptosis [68].
Since the side eﬀects of chronic GTN therapy are mainly
based on adverse regulation of mitochondrial function such
as the inhibition of mitochondrial aldehyde dehydrogenase
(ALDH-2) [23], increase in mitochondrial oxidative stress
[23,27],increaseincellularapoptosis[53],theinductionofa
mitochondrial antioxidant principle (HO-1) would be most
eﬀective to prevent GTN-induced tolerance and endothelial
dysfunction.Thisconceptwassupportedbypreviousreports
on the improvement of GTN side eﬀects by a mitochondria-
targeted antioxidant (mitoQ) [30], by aggravation of GTN
toxicitybypartialdeﬁciencyinthemitochondrialsuperoxide
dismutase(Mn-SOD)[28],andbyinterferenceofblockersof
the mitochondrial pores (cyclosporine A and glibenclamide)
with the crosstalk between cytosolic and mitochondrial
sources of RONS [69]. Vice versa, induction of HO-1 may
explain the beneﬁcial proﬁle of PETN [70]. This concept
is summarized in Figure 3 and was previously published
[31]. To describe the content of this scheme brieﬂy: In
vivo treatment with PETN is devoid of tolerance and
endothelial dysfunction induction in response to chronic in
vivo treatment. In contrast to GTN, PETN does not increase
vascular oxidative stress and therefore does not interfere
with its bioactivation by ALDH-2. A likely explanation for
this beneﬁcial property of PETN is the induction of the
antioxidant enzyme HO-1 and subsequent increases in the
expression of ferritin as well as other protective downstream
mechanisms not shown here (e.g., ecSOD, GCH-1, and
sGC) in vascular tissue but also in the heart. This favorable
characteristics of PETN may also explain why therapy with
GTN but not PETN causes tolerance and stimulates ROS
production in human subjects [9, 71].International Journal of Hypertension 5
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Figure 2: Eﬀects of HO-1 deﬁciency versus HO-1 induction on vascular improvement by pentaerithrityl tetranitrate (PETN). (a, b) PETN
treatment (75mg/kg/d for 4d) had no eﬀect on PETN potency (PETN-induced relaxation) in aorta from control mice (HO-1+/+)b u tc a u s e d
nitratetolerance(seeareabetweencurves)inaortafrommicewithpartialHO-1deﬁciency(HO-1+/−).Inaccordance,cardiacmitochondrial
ROS formation (L-012 ECL) was increased in PETN-treated HO-1+/− mice. P<0.05: ∗versus HO-1+/+/DMSO; #versus HO-1+/−/DMSO.
S: solvent; P: PETN-treated. (c, d) Hemin (25mg/kg i.p.)-triggered HO-1 induction improved high-dose AT-II (1mg/kg/d for 7d)-induced
endothelial dysfunction (ACh-response) in aorta (see area between curves) and NADPH oxidase activity in heart (lucigenin ECL) from
control mice (HO-1+/+). P<0.05: ∗versus AT-II-treated HO-1+/+/DMSO. (e, f) PETN (75mg/kg/d for 7d) failed to prevent endothelial
dysfunction (ACh-response) induced by low-dose AT-II (0.1mg/kg/d for 7d) in aorta from HO-1+/− mice (see area between curves). In
accordance, PETNdidnotimproveNADPHoxidaseactivity(2-HEformationbyHPLCanalysis)incardiacsamplesfromAT-II-treatedHO-
1+/− mice. P<0.05: ∗versus AT-II-treated HO-1+/−/DMSO. All data are mean ± SEM of aortic rings and hearts from 4-5 animals/group.
Modiﬁed from [32].
4.Effects ofOrganicNitrates on
GeneExpression
There are several examples in the literature showing a
transcriptional as well as posttranscriptional modulation of
gene expression by nitric oxide (NO) [72–75]. The activity
of several transcription factors like NF-κB, AP1 [74], or
NRF2 [76] as well as RNA-binding protein like HuR [77]h a s
been shown to be modulated by NO (directly or indirectly
via cGMP). Organic nitrates are believed to be indirect6 International Journal of Hypertension
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Figure 3: Scheme illustrating the mechanisms underlying the oxidative stress concept of nitrate tolerance in response to GTN treatment and
the mechanisms underlying the beneﬁcial vascular eﬀects in response to PETN. PETN and GTN are bioactivated by mitochondrial ALDH
(ALDH-2) yielding 1,2-glyceryl dinitrate and PETriN, respectively, as well as a yet undeﬁned nitrogen species (NOx, probably nitrite) that
undergoes further reduction by the mitochondrial respiratory chain or acidic disproportionation to form an activator of sGC (probably
nitrico xide). GTN treatment induces mitochondrial reactive oxygen and nitrogen species formation (ROS/RNS). These ROS/RNS in turn
inhibit the GTN bioactivation process by inactivation of ALDH-2 or by inhibiting the repair system of the ALDH-2, which includes lipoic
acid, as well as a reductase system depending on the NADH or NADPH (lipoicacid reductase (LAR), thioredoxin/thioredoxin reductase
(Trx/TrxR) or glutathione/glutathione reductase (GSH/GR). In contrast to GTN, PETN provides potent antioxidative eﬀects by inducing
HO-1 and ferritin, which in turn decrease ROS levels and therefore protect the ALDH-2 from ROS mediated inactivation. Adapted from
[31].
NO-donors. Therefore, it seems very likely that treatment
with organic nitrates may have implications on the expres-
sion of multiple genes. GTN has been described to enhance
the expression of c-fos, COX-2, Bcl2, and nNOS in brain
nuclei [78–81], to reduce beta-catenin expression in colon
cancer cells [82], and to reduce NOX1, NOX2, NOX4 and
ALDH2-expression in rat aorta and rat smooth muscle
cells [83]. Using microarray analysis, Wang et al. described
changes of the expression of 290 genes in the aortas of rats
treated with GTN for 8h [84]. Analyzing the gene expression
in the hearts treated for 4 days with GTN, the authors
described expressional changes of more than 500 genes [85].
Therearealsosomereportsabouttheexpressionaleﬀects
of PETN [29, 31, 35, 36, 62]. PETN (but not GTN) has been
shown to enhance the expression of the antioxidant genes
HO-1 and ferritin heavy chain (FeHc) in human endothelial
cells [29, 35, 36, 62] and rat aorta [31]. In microarray
experiments, the authors showed that PETN modulated the
expression of more than 1200 genes in the hearts of rats
treated with PETN for 4 days [85].
5.Molecular Mechanisms Involved in the Regu-
lationofGeneExpressionbyOrganicNitrates
The comparison of the 5 -ﬂanking sequences of the
HO-1 gene (promoter, 10kb) in diﬀerent species (rat,
mouse, rhesus macaque, chimpanzee, and human) displays
regions with very high homology between these species
(“evolutionary conserved regions,” ECRs; see Figure 4).
These ECR are likely to be involved in the regulation of the
HO-1 promoter activity. Bioinformatic analyses show that
these ECR contain the binding sites of transcription factors
(e.g., NRF2) known to regulate HO-1 promoter activity
in diﬀerent mammalian cell systems (e.g., macrophages,
ﬁbroblasts, smooth muscle cells [33]) after various stimuli.
In human SH-SY5Y neuroblastoma [86] or rat vascular
smooth muscle cells [87], the enhancement of the HO-1
expression by diﬀerent NO donors DETA-NO has been
shown to depend on the expression of NRF2.
To analyze the molecular mechanisms of the regulation
of the HO-1 expression by organic nitrates, the authors
cloned a 11kb fragment of the human HO-1 promoter into a
luciferase reporter gene construct. This construct was stably
transfected into human epithelial DLD-1 cells (DLD1-HO-
11kb-Prom). These cells were treated for 8h with PETN,
ISDN, ISMN, or GTN (or the respective solvents, dimethyl
sulfoxide DMSO, H2O, ethanol EtOH). Cell extracts were
prepared, and luciferase activity was measured. As shown in
Figure 5, only PETN was able to enhance the promoter activ-
ity of the human HO-1 gene. Therefore, the enhancement of
HO-1 expression by PETN seems to depend at least partly
on PETN-induced enhancement of the HO-1 promoter. A
similar comparison of the eﬀects of diﬀerent organic nitrates
on HO-1 induction was recently published [34].
To analyze the involvement of the transcription fac-
tor NRF2 in this PETN-mediated enhancement of HO-1International Journal of Hypertension 7
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Figure 4: Comparison of the HO-1 promoter sequences of diﬀerent species. (a) Comparison of the 5 -ﬂanking sequences (10kb) of the
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diﬀerent cells systems (see also [33]).
50
100
150
ns ns ns
DMSO
H
O
-
1
 
p
r
o
m
o
t
e
r
 
a
c
t
i
v
i
t
y
i
n
 
c
o
n
t
r
o
l
 
c
e
l
l
s
 
(
%
)
ISDN PETN ISMN EtOH GTN H2O
∗∗∗
Figure 5: Eﬀects of organic nitrates on the human HO-1 promoter activity. DLD1-HO-11kb-Prom cells were treated for 8h with isosorbide
dinitrateISDN,PETN,isosorbide-5-mononitrateISMN,orGTNataconcentrationof50μMortherespectivesolvent(DMSO,H2O,EtOH).
Extracts were prepared, and luciferase activity and protein content were measured, and luciferase activity was normalized to the protein
content. Shown (mean ± SEM; n = 8–10) are the normalized luciferase activity values. The normalized luciferase activity of the cell treated
with solvent was set to 100%. (∗∗∗= P<0.001, ns: not signiﬁcant diﬀerent from solvent-treated cells.) These data were partly published in
[34].8 International Journal of Hypertension
promoter activity, NRF2-knockdown experiments using a
speciﬁc anti-NRF2 siRNA were performed. These experi-
ments clearly showed that the PETN-mediated enhancement
of the human HO-1 promoter activity depends on the
NRF2 expression (see Figure 6)[ 34]. Therefore, it is likely
to speculate that the NO generated by PETN activates NRF2
which in turn binds to the HO-1 promoter and enhances
transcription.
Beside transcriptional regulation, the modulation of
expression of HO-1 has been shown to depend on post-
transcriptional mechanisms [77, 88–92]. Posttranscriptional
regulation of mRNA stability and translatability mostly
depends on sequences found in the 3 -untranslated sequence
(3 -UTR) of the mRNAs [93, 94]. Analysis of the 3 -
UTR sequences of the HO-1 mRNA of diﬀerent species
(rat, mouse, rhesus macaque, chimpanzee, and human,
see Figure 7) reveals evolutionary conserved regions (ECR).
In the 3 -UTR sequences of all species, AU-rich elements
(AREs) is highly conserved. AREs have been shown to be
the binding sites of RNA, binding proteins like HuR or
KSRP, which stabilize or destabilize the mRNAs. In a recent
paper, the NO-dependent stabilization of the HO-1 mRNA
in murine ﬁbroblasts was shown to depend on the RNA-
binding protein HuR [77].
To analyze the eﬀects of organic nitrates on the HO-1
mRNA stability, the authors cloned the 3 -UTR sequence of
the human HO-1 mRNA behind the luciferase reporter gene
(pGL3-Control-HO-1-3-UTR). Stable human endothelial
cells (EA.hy 926) were transiently transfected with this
construct and treated with GTN or PETN (see Figure 8).
PETN but not GTN enhanced luciferase activity in the
transfected cells indicating a PETN-dependent stabilization
of the HO-1 mRNA (unpublished data, Hartmut Kleinert).
6. Conclusions andClinicalImplications
Organic nitrates like GTN or PETN seem to have marked
distinct pharmacological properties and side eﬀects [50],
translating to diﬀerent therapeutic proﬁles and clinical prop-
erties (e.g., induction or lack of nitrate tolerance) [9], which
may be at least in part explained by their diﬀerent eﬀects
on HO-1 gene expression [2]. This may be attributed to
the diﬀerent amounts of bioactive NO generated from these
compounds. As GTN markedly enhances ROS production
in cells, only small amounts of bioactive NO are produced.
In contrast, PETN incubation results in decent amount of
bioactive NO (or a related species such as S-nitrosothiols or
heme-NO) resulting in enhanced NRF2 binding to the HO-1
promoter and HuR binding to the HO-1 mRNA. Thereby,
PETN enhances HO-1 expression both by transcriptional
and posttranscriptional eﬀects (see Figure 9). Since HO-1
and its products may directly regulate other genes [47],
distinct modulation of HO-1 expression by diﬀerent organic
nitrates may also explain diﬀerential regulation of gene
expression by organic nitrates in general (e.g., GTN versus
PETN) [85].
First clinical evidence for the importance of HO-1 to
overcome nitrate tolerance is based on the observation that
statin therapy (well-known inducers of HO-1) was able to
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Figure 6: PETN-induced enhancement of the human HO-1
promoter activity depends on NRF2. DLD1-HO-11kb-Prom cells
were transfected with a speciﬁc anti-NRF2 siRNA (siNRF2) or
a nonrelated control siRNA (siCon). After 48h, the cells were
incubated with PETN or the solvent DMSO. Extracts were prepared
and luciferase activity and protein content were measured, and
luciferase activity was normalized to the protein content. Shown
(mean ± SEM; n = 5-6) are the normalized luciferase activity
values. The normalized luciferase activity of the cell treated with
solvent and siCon was set to 100%. (∗∗= P<0.01, ∗= P<
0.05, ns: not signiﬁcant diﬀerent to DMSO and siCon-treated cells.
Modiﬁed from [34].
prevent nitrate tolerance in human subjects [40, 41]. Despite
the fact that published preclinical data clearly show that
an organic nitrate with HO-1 inducing properties such as
P E T Nh a sl e s ss i d ee ﬀects [31] and even has beneﬁcial
eﬀectson experimental hypertension [32],diabetes[34],and
atherosclerosis [95], these ﬁndings still lack molecular proof
in human subjects to increase the clinical importance of this
concept. A proof of concept study aiming to demonstrate
that individuals with Morbus Meulengracht (Gilbert’s syn-
drome), displaying increased HO-1 activity and bilirubin
levels, are devoid of tolerance, endothelial dysfunction and
oxidative stress in response to nitroglycerin (GTN) therapy
could provide a new therapeutic option to overcome these
undesired side eﬀects of GTN treatment.
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